Lazertinib: A narrative drug review

Abstract

ABSTRACT Epidermal growth factor receptor (EGFR) activating mutations are established drivers in non-small-cell lung cancer (NSCLC); 85% of these mutations are exon 19 deletion or exon 21 L858R point substitution. Lazertinib (YH-25448, JNJ-73841937, LECLAZA®) represents one of the latest oral third-generation EGFR-tyrosine kinase inhibitor (TKI) binding irreversibly to the Cys797 residue in the adenosine triphosphate (ATP)-binding site of the EGFR kinase domain, with high selectivity for EGFR mutations including T790M. To write this narrative review, we searched online portals of ScienceDirect, PubMed, and Google Scholar and various websites such as the United States Food and Drug Administration (US-FDA) and UpToDate, using the search terms “Lazertinib,” “YH-25448,” “JNJ-73841937,” and “NSCLC.” We shortlisted 30 articles published between January 2021 and December 2023, of which we included 10 articles. This review elaborates on the indications for use, side effects and safety profile, drug interactions, and pharmacokinetics and dynamics. Key evidence that investigated the use of lazertinib has also been discussed.